

10/520624

PCT/AU03/00892



Patent Office  
Canberra

REC'D 31 JUL 2003

WIPO


PCT

I, JULIE BILLINGSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2002950095 for a patent by CRYPTOME PROTEOMICS PTY. LTD. as filed on 10 July 2002.

I further certify that the name of the applicant has been amended to CRYPTOME RESEARCH PTY. LTD. pursuant to the provisions of Section 104 of the Patents Act 1990.

WITNESS my hand this  
Twenty-second day of July 2003

JULIE BILLINGSLEY  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES



**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**Regulation 3.**

**CRYPTOME RESEARCH PTY. LTD.**

**A U S T R A L I A**

**Patents Act 1990**

**PROVISIONAL SPECIFICATION**

**for the invention entitled:**

**"Method for detection of bioactive peptides"**

**The invention is described in the following statement:**

## METHOD FOR DETECTION OF BIOACTIVE PEPTIDES

### FIELD OF THE INVENTION

5 This invention relates to a method for the detection of bioactive peptides. More particularly, the present invention relates to a screening method for the identification of bioactive peptides derived from precursor proteins or protein-containing biological extracts. Such bioactive peptides have potential for use in various therapeutic and/or diagnostic applications, for example, in connection with arterial and venous thrombosis, and cancer.

10

### GENERAL

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description. All patents, patent applications, and publications cited herein are  
15 incorporated by reference in their entirety.

Throughout this specification, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or  
20 group of integers or steps.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features,  
25 compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps, features, compositions and compounds.

The present invention is not to be limited in scope by the specific embodiments described herein,  
30 which are intended for the purposes of exemplification only. Functionally equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

## BACKGROUND OF THE INVENTION

The recent sequencing of the human genome has revealed around 30,000 genes, far fewer than would be predicted from the complexity of human biological processes. Alternate splicing of these genes prior to translation would likely generate up to 200,000 primary transcripts, still a long way short of the predicted 1 – 1.5 million protein/peptide activities present in the human proteome. It is now widely accepted that post translational modifications to the protein products coded by these genes represents the additional level of complexity required, to explain the diversity of function. The most common post- or co-translational event is protease mediated protein cleavage resulting in the generation of smaller protein/peptide bioactivities. These cleavage products possess distinct activities (agonists/antagonists etc.) that can not be identified by analysis of the genetic code.

The present invention is based on a novel platform technology, described as "cryptomics", which provides a series of integrated procedures that together enable the generation , identification and characterisation of bioactive peptides derived from larger precursor proteins.

The rationale behind the present invention is that controlled proteolytic digestion of naturally occurring proteins with proteases will result in the liberation of cryptic bioactive peptides that ordinarily lie hidden within intact and folded proteins. Accordingly, the present invention includes the systematic generation of peptide (small protein fragments) libraries following proteolytic and/or chemical cleavage of both single proteins and protein containing biological extracts. These libraries are then fractionated and the bioactive moieties identified in high throughput biological screening assays. Active fractions can then be isolated and fully characterised by classical proteomic technologies prior to activity validation in more sophisticated assay systems. Bioactive peptides thus identified can then be used as biological "leads" including, but not limited to, the generation of potential therapeutics and diagnostics.

## SUMMARY OF THE INVENTION

In one aspect the present invention provides a method for the detection of bioactive peptides derived from a precursor protein or protein-containing biological extract, comprising the steps of:

- (i) providing a library of peptides derived from said precursor protein or protein-containing biological extract;
- (ii) optionally screening said library to confirm that it includes peptides exhibiting one or more predetermined biological activities;
- (iii) separating said library by chromatography to provide fractions of the library;
- (iv) screening said fractions to identify active fractions which include peptides exhibiting said one or more biological activities;
- (v) optionally separating each said active fraction by chromatography to provide sub-fractions thereof, and screening said sub-fractions to identify active sub-fractions which include peptides exhibiting said one or more biological activities; and
- (vi) isolating from said active fractions or active sub-fractions one or more peptides exhibiting said one or more predetermined biological activities.

The term "peptide" as used herein shall be taken to refer to any polymer consisting of amino acids linked by covalent bonds and this term includes within its scope parts or fragments of full length proteins, such as, for example, polypeptides, oligopeptides and shorter peptide sequences consisting of at least 2 amino acids, more particularly at least about 5 amino acid residues. In addition, this term includes within its ambit polymers of modified amino acids, including amino acids which have been post-translationally modified, for example by chemical modification including but not restricted to glycosylation, phosphorylation, acetylation and/or sulphation reactions that effectively alter the basic peptide backbone. Accordingly, a peptide may be derived from a naturally-occurring protein, and in particular may be derived from a full-length protein by chemical or enzymatic cleavage, using reagents such as CNBr, or proteases such as trypsin or chymotrypsin, amongst others. Alternatively, such peptides may be derived by chemical synthesis using well known peptide synthetic methods.

Also included within the scope of the definition of a "peptide" are amino acid sequence variants

(referred to herein as peptide variants), containing one or more preferably conservative, amino acid substitutions, deletions, or insertions, in a naturally-occurring amino acid sequence which do not alter at least one essential property of said peptide, such as, for example, its biological activity. Such peptides may be synthesised by chemical peptide synthesis. Conservative amino acid substitutions are well-known in the art. For example, one or more amino acid residues of a native protein can be substituted conservatively with an amino acid residue of similar charge, size or polarity, with the resulting peptide retaining functional ability as described herein. Rules for making such substitutions are well known. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in their side chains. Genetically-encoded amino acids are generally divided into four groups: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, and histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, and tyrosine. Phenylalanine, tyrosine and tryptophan are also jointly classified as aromatic amino acids. One or more replacements within any particular group such as, for example, the substitution of leucine for isoleucine or valine are alternatively, the substitution of aspartate for glutamate or threonine for serine, or of any other amino acid residue with a structurally-related amino acid residue while generally have an insignificant effect on the function of the resulting peptide.

The present invention is not limited by the source of the peptide, and clearly extends to peptides and peptide mixtures which are derived from a natural or a non-natural occurring source.

The term "peptide" also includes polypeptides, oligopeptides or shorter peptide sequences derived from a recombinant protein. The term "recombinant protein" as used herein shall be taken to refer to a recombinant protein. Protein which is produced *in vitro* or in a host cell by the expression of a genetic sequence encoding said protein, which genetic sequence is under the control of a suitable promoter, wherein a genetic manipulation has been performed in order to achieve said expression. Accordingly, the term "recombinant protein" clearly encompasses proteins produced by the expression of genetic sequences contained in viral vectors, cosmids or plasmids that have been introduced into prokaryotic or eukaryotic cells, tissues or organs. Genetic manipulations which may be used in this context will be known to those skilled in the art and include, but are not limited to, nucleic acid isolation, restriction endonuclease digestion, exonuclease digestion, end-filling using the Klenow fragment of *E. coli* DNA polymerase I to T4 DNA polymerase enzymes, blunt-ending of DNA

molecules using T4 DNA polymerase or ExoIII enzymes, site-directed mutagenesis, ligation, and amplification reaction.

When the peptides of the present invention are derived from a recombinant protein, it may be produced in and, if desirable, isolated from a recombinant viral vector expression system or host cell. As will be known to those skilled in the relevant art, a cell for production of a recombinant protein is selected on the basis of several parameters including the genetic constructs used to express the protein under consideration, as well as the stability and activity of said protein. It will also be known to those skilled in the art, that the stability or activity of a recombinant protein may be determined at least in part, by post-translational modifications to the protein such as, for example, glycosylation, acylation or alkylation reactions, amongst others, which may vary between cell lines used to produce the recombinant protein.

As used herein, the term "derived from" shall be taken to indicate that a particular peptide or mixture of peptides which has been obtained from a particular protein, protein mixture or protein-containing biological extract, either directly (for example, by proteolytic, chemical or physical digestion of the protein(s) or extract), or indirectly (for example, by chemical or recombinant synthesis of peptides having amino acid sequences corresponding to naturally-occurring sequences, or peptide variants thereof).

The screening method of the present invention may be used to detect peptides having a wide range of target biological activities, including both agonist and antagonist activity. By way of example only, target areas may include arterial and venous thrombosis, inflammation, angiogenesis and cancer, however the present invention is not restricted to screening in these target areas. Suitable screening assays include, but are not limited to, luminescence based assays to detect ATP released on activation of the platelets which are able to detect activators (agonists) or inhibitors (antagonists) of platelet activation, as well as coagulation assays for prothrombin time (PT) and activated partial thromboplastin time (APTT).

Preferably, in the method of the present invention, the initial library of peptides comprises a heterogeneous and unfractionated mixture of peptides derived from a precursor protein (or protein mixture or protein-containing biological extract) which provides a comprehensive range of potentially

bioactive peptides.

Preferably also, the library is subjected to initial analysis or characterisation to provide information on the size and other characteristics of the component peptides, for example by matrix assisted laser  
5 absorption time of flight mass spectrometry (MALDI TOF-MS). Initial screening of the library to confirm that it includes bioactive peptides may also be carried out using any suitable screening assay or assays, including in particular cell-based assays, to detect the predetermined biological activity or activities.

10 After the library has been confirmed as including bioactive peptides, it is fractionated by chromatographic methods such as, but not limited to, size exclusion, ion exchange, hydrophobic interaction and/or reverse phase-high performance liquid chromatography, in order to provide fractions of the library for subsequent further screening. This further screening may be carried out  
15 active fractions which include bioactive peptides.

Since such active fractions are likely to include more than one peptide, each fraction may, if desired, be subjected to one or more further cycles of fractionation by chromatography to form sub-fractions, followed by screening of each sub-fraction as described above so as to identify an active sub-  
20 fraction or active sub-fractions which include bioactive peptides.

Each fraction or sub-fraction which is produced may also be subjected to analysis or characterisation as described above, for example by MALDI-TOF MS, so as to provide information on the size and other characteristics of the component peptides in the fraction or sub-fraction.

25

Finally, in accordance with the invention, one or more bioactive peptides are isolated from an active fraction or active sub-fraction using protein/peptide purification methods which are well known to persons skilled in this art, followed if desired by further bioassays to confirm the bioactivity of the isolated peptide(s).

30



## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** is a schematic depiction of one embodiment of the process of the present invention for the detection of bioactive peptides for therapeutic and diagnostic use.

5

**Figure 2** shows by way of example the generation of digestion mixtures of the protein, fibrinogen.

**Figure 3** shows by way of example the chromatographic fractionation of fibrinogen digestion  
10 mixtures into libraries.

**Figure 4** shows by way of example the luminometric determination of ATP release from platelets in response to collagen in the presence or absence of RGDS.

15 **Figure 5** shows by way of example the luminometric determination of collagen-induced ATP release from platelets following co-incubation with fractionated fibrinogen-derived peptides.

**Figure 6** shows an example of a MALDI-reflector-mass spectrum of a fraction from digests of fibrinogen.

20

## DETAILED DESCRIPTION OF THE INVENTION

The scheme outlined below comprises one embodiment of the present invention for the generation, isolation and identification of bioactive peptides derived from proteins and protein mixtures (see also  
25 **Figure 1**). This scheme involves:

**Step 1** The digestion by, but not limited to, proteolytic, chemical or physical means, of single proteins and/or protein containing biological extracts to produce a digestion mixture (that is, a library of peptides).  
30

**Step 2** The biochemical characterisation of the peptides contained within the digestion mixture.

Step 3            Screening of the digestion mixture for biological activities.

Step 4            Chromatographic fractionation of the digestive mixture into component peptide  
5    fractions.

Step 5            Assay of fractions for both peptide mass fingerprints and biological activity.

Steps 6/7        Subsequent re-fractionation and assay of activity-containing fractions.

10

Step 8            The full identification and analysis of the bioactive peptide(s).

15    Taken together, these eight steps provide a process by which bioactive peptides may be detected from both simple and complex protein mixtures. Incorporated within the described method is the collection of peptide mass and abundance information at Steps 2, 4,6 and 8 and detection of bioactivity at Steps 3,5,7 and 8, such that the precise identity and activity of an observed bioactive peptide can be determined.

#### Step 1.- Digestion of protein(s)

20

25    The source protein may take any form; it may be single naturally expressed protein purified from a complex biological extract, or a recombinant (such as but not limited to bacterial, insect or mammalian expression systems) form of a specified protein. Alternatively, a complex protein mixture from biological fluids, tissue or cellular extracts may be used as the protein source. The protein may be cleaved into peptide components using, but not limited to, purified proteases, protease activity-containing extracts, chemical cleavage or other mechanism of protein fragmentation. The overall approach is to generate a library of peptides that comprises a heterogeneous and unfractionated mixture of peptides from the intact protein(s). Such a library can comprise partial, intermediate and/or complete digestions of the protein source thus providing as comprehensive a range of protein  
30    fragments as possible. A wide range of fragments can be achieved by varying a range of conditions including digestion times, pH, buffer and temperature conditions and substrate to enzyme ratios. Additionally, cleavage of the protein may be performed by a range of cleavage agents (including but

not limited to protease and chemical cleavage) each having a defined and different protein cleavage specificity. Cleavage may also be performed either in series or in parallel, such that different combinations of these digestion methodologies can be used to generate distinct peptide species. Accordingly, each variation on a digestion condition will generate a distinct library of peptides from a particular protein source.

### Step 2.- Selection of digestion conditions

Unfractionated peptide libraries may be subjected to analysis, including but not limited to matrix assisted laser desorption time of flight mass spectrometry (MALDI TOF-MS); this analysis provides precise information on the size and possible identity of the component peptides. In the case of MALDI TOF-MS analysis, spectra for a number of libraries may be compared and optimal sets of digestion condition parameters determined where marked changes in peptide profile (number/size/pattern complexity etc.) occur. These sets of digestion condition parameters can be used to generate predictable 'hot-spots' where digestion should be focussed to limit the number of libraries for subsequent fractionation. In addition, these MALDI TOF-MS spectra provide an exact record of the profile of each library of peptides, providing both a level of quality control and allowing the generation of reproducible preparations for down stream analysis in cases where cellular activity assays identify "hits" for bioactive peptides in the library of peptides.

### Step 3. - Identification of fractions containing bioactivity

To reduce the number of libraries to be fractionated and screened, whole unfractionated digestion mixtures are preferably subjected to appropriate initial bioactivity assays such as cell-based assays (refer Figure 1). This step then precedes fractionation and bioactive peptide identification and allows identification of digestion mixtures for fractionation, thus reducing the number of fractionations required for the identification of each bioactive peptide. It should be noted that the 'usefulness' of a digestion mixture as determined by 'bioactivity' is dependent on the bioactivity assay used, and an apparently uninteresting digestion mixture may become interesting if it is positive when used as an input in a new assay. In addition, the co-existence of an agonist peptide and an antagonist peptide in a single digestion mixture may cancel each other out so that together there may be no net bioactivity in any particular assay, however, after fractionation, such activities may manifest themselves when

separate fractions are assayed for bioactivity.

High throughput, automated screening assays are preferably used to identify potential bioactivities with relevance to several major therapeutic applications. The library of peptides may be subjected to a wide array of both biochemical and cell-based assays, providing extremely wide scope for potential hits in multiple target areas. By way of example only, initial high throughput screens may consist of luminescence based assays for platelet activation, laser-based methods for Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APPT), and luminescence and fluorescence based detection of cell proliferation, cell toxicity and apoptosis. In all cases, each library may be screened for agonist and antagonist actions, thus providing the potential to identify bioactive peptides and develop activities that may have either therapeutic or diagnostic value.

#### Step 4. - Initial fractionation of digestion mixtures

Each library of peptides found to contain a biological activity in Step 3 is then fractionated by chromatographic methods including but not limited to, size exclusion, ion exchange, hydrophobic interaction and/or reverse phase-high performance liquid chromatography. To interface directly with the biological screening assays detailed in Step 3, fractions (for example 2ml in the first instance) are preferably collected in a format that is compatible with direct robot driven transfer into the assays for biological activity outlined in Step 3. While not restricted to any particular format, use of 96 deep-well plates is preferred as the aim, wherever possible, is to use chromatographic solvents that will be either compatible with subsequent bioassays or suitable for freeze-drying. At this point the collected fractions may be freeze-dried and stored. When required, the freeze-dried material can be resuspended in a cell-compatible isotonic and buffered solution.

#### Step 5. - Assay of collected fractions for both analysis and biological activity.

Using either a split flow system, or by direct analysis of an aliquot taken from the collected fractions, a comprehensive data set may be collected on the composition of the component peptides in each fraction (mass spectrometry), thus each fraction has a unique finger print which can be used to match activity with mass. The collected fractions are also subjected to a range of cell-based or other activity assays as described in Step 3 in order to identify fractions containing biological activity (i.e.

active fractions).

Steps 6/7 - Subsequent re-fractionation and assay of activity-containing fractions.

- 5 Since active fractions identified in Step 5 are likely to contain more than one peptide, the fractions are preferably subjected to one or more further rounds of chromatography (second and subsequent dimensions) to form sub-fractions, with each round involving monitoring of the composition of each sub-fraction by MALDI-TOF MS, and identification of active sub-fractions using activity assays as described in Step 3.

10

Step 8. - The full identification and analysis of the bioactive peptide(s).

- Any peptide moiety found to have agonist and/or antagonist activities in the cell-based or other bio-assay(s) performed in Step 5 is subjected to further analysis. Peptide sequence identification of a given putative bioactive peptide can be achieved through a combination of MALDI TOF - post source decay - MS data and alignments to the Human Genome Database. Putative bioactive peptides can be validated by synthesising analogues and substitution/sequence reversal variants and examining their ability to replicate the initial agonist/antagonist activities initially observed in the cell-based or other assays performed in Step 5. Finally, active peptides may be subjected to further evaluation in more sophisticated (tissue/organ/whole animal) bioassays.
- 15
- 20

- The following Example is provided in order to assist in a full and complete understanding of the method of the present invention. It is to be understood that the invention is not to be limited in scope by this Example, but extends broadly to the detection of bioactive peptides derived from a precursor protein or protein-containing biological extract as described above.
- 25

### EXAMPLE

This Example describes the generation, identification and activity of expected RGD-containing anti-thrombotic peptides in proteolytic digests of the purified protein, fibrinogen, as "proof of concept" of the method of the present invention.

Fibrinogen is an  $\alpha 2\beta 2\gamma 2$  heterodimeric plasma glycoprotein, which has multifunctional roles in regulating thrombosis. It bridges the interaction between aggregating platelets through an internal arginine-glycine-aspartic acid (RGD) sequence, which binds to the platelet aggregation receptor, the integrin GP IIb-IIIa. Proteolytic fragments of fibrinogen, particularly peptides containing the RGD motif, are therefore predicted to antagonise several of the anti-thrombotic screening assays.

To liberate the expected RGD-containing fibrinogen fragments, a library of partial and complete Lys-C- and trypsin-digested fragments was generated. A range of digestion products were generated by varying digestion condition parameters, and the resulting digestion mixture fractionated by reversed phase high performance chromatography to form a digest library for screening.

Miniaturised (96 well format) high-throughput screening assays capable of assessing platelet activation that are suitable for screening potential anti-thrombotic agents have been developed. The primary assay is based on the phenomenon that platelet activation results in a substantial release of ATP from dense granules. Released ATP is then rapidly quantitated in a plate reader using bioluminescence and is proportional to the extent of platelet activation.

The identity of the peptides was established by comparing peptide masses measured by MALDI TOF mass spectrometry to a list of values obtained from a theoretical digest of fibrinogen. The mass accuracy achieved by using a reflector instrument was within 100 ppm, resulting in a very high degree of certainty of the peptide identification and integrity. Any remaining ambiguities of the peptide identity can be eliminated by fragment analysis using the same instrument.

30

Figure 2 shows by way of example the generation of fibrinogen digestion mixtures. Fibrinogen was protease-digested under various conditions to generate a range of partial and complete digest

products and mixtures. These digestion mixtures individually and in combination are constituted of a diverse range of complete and partially digested peptides of different amino acid sequences. Such a process has the capacity to reveal cryptic peptides not otherwise detected in nature. Some of these conditions are described below: (A) fibrinogen was treated with Lys-C over a range of times to generate a heterogeneous mixture of full and partial digest products; (B) fibrinogen, in both reduced and non-reduced forms, was digested with Lys-C and trypsin to produce a range of unique and distinct peptide species; (C) fibrinogen was digested with Lys-C at various enzyme to substrate ratios to produce a range of digested peptide species.

Figure 3 shows by way of example chromatographic fractionation of digestion mixtures into digest libraries of peptides. Fibrinogen was protease-digested with Lys-C or trypsin at a substrate to enzyme ratio of 1:100 for 16 hrs. These digestion mixtures were chromatographically separated by Reversed Phase -HPLC using a C18 (5 $\mu$ , 2.0 x 150mm) column using an eluent of ACN (0-100% ACN in 30 min with 0.1% TFA) at 0.5 mL/min and collected in 250  $\mu$ L fractions.. An aliquot of each library fraction was kept for mass spectrometric analysis and the balance dried and stored at -80°C.

Figure 4 shows by way of the luminometric determination of ATP release from platelets in response to collagen. Platelet rich plasma was stimulated by automated injection of 2  $\mu$ g/ml collagen in the presence or absence of commercially available RGDS (30  $\mu$ M). Relative light output was then measured automatically in a BMG Fluostar plate reader. RGDS partially inhibited collagen-induced ATP release by 30% (\*:  $p < 0.002$  versus collagen alone).

Figure 5 shows by way of the luminometric determination of collagen-induced ATP release from platelets (see Fig. 4) following coincubation with fractionated fibrinogen-derived peptides. Fibrinogen was digested with either Lys-C (A) or trypsin (B) prior to fractionation as described in Figs. 2 and 3. The fractions highlighted by horizontal arrows partially inhibited collagen-induced ATP release and were shown by MALDI-TOF mass spectrometry to comprise RGD containing peptide species (see Fig. 6). In addition, several fractions (29, 30 in A; 27, 29 in B) were shown to enhance collagen-induced ATP release, demonstrating that both agonist and antagonist activities can be identified after fractionation.

Figure 6 is an example of a MALDI-reflector-mass spectrum of a fraction from digests of fibrinogen.

- 14 -

The spectrum was obtained using the Anchorchip method developed by Bruker-Daltonics. In short, an aliquot of 0.25 µl of sample is mixed with 2µl of alpha-cyano cinnamic acid prior to deposition on the Anchorchip plate which locates the sample to a 400 µm spot. The spectrum was recorded using an Autoflex (Bruker-Daltonics) mass spectrometer run in an automatic mode. The peak at 2042.6  
5 corresponds to the second isotope of the RGDS containing peptide alpha chain 547-564. The insert shows the isotopic peaks and indicates the high mass accuracy obtained.

Dated this 10<sup>th</sup> day of July 2002.

10 **Cryptome Research Pty. Ltd.**

By its Patent Attorneys

*Davies Collison Cave*



Figure 1





Figure 2



3/6

Figure 3




Figure 4




Figure 5




Figure 6

